Sector News

Endo keeps up its Valeant act with asset-sale talks

June 29, 2016
Life sciences

No one has the Valeant act down quite like Endo. After a guidance-slashing reminiscent of the Canadian pharma’s, the Dublin drugmaker is now following up with asset-sale discussions.

Endo has held talks with private equity firms about potential divestments that could help cut down its $8 billion-plus mountain of debt, Reuters’ sources say. It’s been looking into several options, including an asset swap with another company–though discussions are still in the early stages.

Endo–whose CEO, Rajiv De Silva, previously served as the COO at Valeant–has long seemed to be following in the footsteps of its specialty pharma peer, piling up debt in its race to gobble up smaller companies.

But these days, that’s no longer a good thing. Valeant has gone from Wall Street darling to bottom-feeder as debt-default concerns and dismal sales have taken their toll, and its new CEO–Perrigo vet Joseph Papa–has touted potential asset sales as a way to pay down debt and reduce some of the complexity of Valeant’s business.

Endo, too, reported disappointing quarterly sales last month that forced it to lower its 2016 EPS and revenue benchmarks. Shareholders–as Valeant’s did after a similar takedown in March–bolted for the exits. Shares crashed by nearly 40% as management attributed the change to new rivals on the market, greater-than-expected generics price erosion and regulatory delays.

Now, it remains to be seen if asset sales can turn Endo’s performance around–though after last month’s events, some analysts may be hard to convince.

“Weak longer term outlook, drastically lowered guidance, and pushed out de-levering targets (4.6x leverage) are the key reasons we view the stock as toxic,” Mizuho analyst Irina Koffler wrote after the guidance adjustments, adding that she “can’t see a reason” to own Endo shares.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach